Overview

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.

Status:
Completed

Trial end date:
2017-09-30

Target enrollment:

Participant gender:

Summary

Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects being Overweight or with Obesity

Phase:

Phase 1

Details

Lead Sponsor:

Novo Nordisk A/S